Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerDavid Miles, Gilles Romieu, Arlene Chan et al.|Journal of Clinical Oncology|2010Cited by 887
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Klaus Pantel, Jean‐Yves Pierga et al.|Critical Reviews in Oncology/Hematology|2018Cited by 268
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II StudyC. Kent Osborne, Mark Sellers, Luc Dirix et al.|Clinical Cancer Research|2011Cited by 181
Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sortingDieter Peeters, Luc Dirix|British Journal of Cancer|2013Cited by 170
Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profilingSteven Van Laere, Luc Dirix|Breast Cancer Research and Treatment|2005Cited by 107